

Addition of a Selective 5-HT_{2A}/D₄ Antagonist Accelerates the Antidepressant Effects of Citalopram

Alan G. Wade, MD,¹ Charles B. Nemeroff, MD, PhD,² Alan F. Schatzberg, MD,³ Thomas Schlaepfer, MD,⁴ Gordon M. Crawford, MD,¹ Alex McConnachie, PhD,⁵ Ian Ford, PhD,⁵ Ludo Haazen, MD,⁶ Erik Buntinx, MD⁶

¹CPS Research, Glasgow, UK; ²Emory University School of Medicine, Department of Psychiatry & Behavioral Sciences, Atlanta, GA, USA; ³Stanford School of Medicine, Department of Psychiatry & Behavioral Sciences, Stanford, CA, USA; ⁴The Johns Hopkins University School of Medicine, Department of Psychiatry, Baltimore, MD, USA, and University of Bonn, Germany; ⁵Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK; ⁶PharmaNeuroBoost N.V., Alken, Belgium

Improvement in symptoms of depression is typically delayed with antidepressant treatment, and that delay is associated with prolonged morbidity, increased risk for suicide and substance abuse, decreased compliance, and early treatment discontinuation. One theory for the delay in clinical response is that stimulation of 5-HT_{2A} receptors induces a temporary feedback loop, reducing the effect of increased serotonin at the synapse. This raises the possibility of increasing the early efficacy of selective serotonin reuptake inhibitors (SSRIs) by blocking this mechanism. Pipamperone (PIP) at very low doses acts as a highly selective 5-HT_{2A}/D₄ receptor antagonist. The purpose of this 8-week, double-blind, parallel-group, single-dummy study was to investigate whether the addition of PIP 5 mg BID to citalopram (CIT) 40 mg daily (PIPCIT) would increase the rate of resolution of depressive symptoms. The mean total Montgomery-Asberg Depression Rating Scale (MADRS) score (SD) of the 165 patients (81% women; mean age, 40 y; mean body weight, 80 kg) was 32.6 (5.5). More CIT than PIPCIT patients discontinued treatment in the first 4 weeks (15 [18%] vs 3 [4%]; $P=0.003$). Reductions in mean total MADRS scores were significantly (intent to treat; last observation carried forward) larger in patients receiving PIPCIT after 1 week (-6.42 [6.18] vs -3.99 [5.15]; $P=0.007$) and 4 weeks (-15.06 [8.48] vs -12.11 [8.30]; $P=0.025$) compared with those receiving CIT alone. Significant differences in favor of PIPCIT were observed in MADRS items "reduced sleep," "reduced appetite," "concentration difficulties," and "pessimistic thoughts." Mean Clinical Global Impression-Improvement (CGI-I) scores were also improved after 1 week of PIPCIT (3.09 [0.85] vs 3.47 [0.72]; $P=0.002$). There were no significant differences observed at 8 weeks. No additional clinically significant adverse events were noted in the PIPCIT group. A very low dose of PIP added to CIT provided superior antidepressant effects and fewer discontinuations compared with CIT alone during the first 4 weeks of treatment, and especially in the first week, at apparently no tolerability/safety cost.

This research was sponsored by PharmaNeuroBoost N.V.

Addition of a Selective 5-HT_{2A}/D₄ Antagonist Ac

Alan G. Wade, MD,¹ Charles B. Nemeroff, MD, PhD,² Alan F. Schatzberg, MD,³ Thomas Schlaepfer, MD,⁴

¹CPS Research, Glasgow, UK, ²Emory University School of Medicine, Department of Psychiatry & Behavioral Science

³The Johns Hopkins University School of Medicine, Department of Psychiatry, Baltimore, MD, USA, and ⁴University of Bonn,

Introduction

- Many patients with major depressive disorder (MDD) do not demonstrate a clinically significant response to antidepressant drugs until 24 weeks after initiation of treatment.¹
- Slow antidepressant therapeutic effect can reduce compliance and possibly increase the risk for suicide or suicidal behavior.^{2,3} Early symptom improvement (<4 wk) has been associated with eventual antidepressant response.⁴
- Serotonin reuptake inhibitors act by preventing the pre-synaptic reuptake of serotonin, increasing synaptic availability; this results in increased stimulation and densitization of the postsynaptic 5-HT_{1A} receptor.⁵
- Increased serotonin also stimulates 5-HT_{2A} receptors, leading to inhibition of 5-HT_{1A} receptor stimulation by a negative feedback mechanism.⁶
- Hence, administration of a 5-HT_{1A} antagonist could disinhibit 5-HT_{1A} receptors⁷ and speed the therapeutic effect.
- However, because 5-HT_{2A} antagonists increase dopaminergic neurotransmission, it could precipitate D₂ receptor-mediated behavioral dysregulation.
- The mild neuroleptic pimeloperazine (PP)—of very low doses does not currently used clinically—is a highly selective 5-HT₂ and D₂ antagonist.^{8,9} We hypothesized that administration of PP with the antidepressant clomipramine (CIT) would improve the antidepressant effect and hasten the resolution of symptoms.

Objective

- To investigate whether the addition of PP (5 mg twice daily [BID]) to CIT 40 mg once daily (QD) improves antidepressant efficacy and speeds the rate of resolution of depressive symptoms relative to CIT monotherapy in patients with MDD.

Methods

Study Design

- Phase II multicenter, randomized, double-blind, parallel-group, placebo-controlled study with 8-week treatment phase and 4-week safety follow-up
 - This report includes only secondary outcomes.

Main Inclusion Criteria

- Men and women 18–65 years of age with moderate to severe MDD according to the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition)
- Current nonpsychotic depressive episode lasting 4–26 weeks
- Clinical Global Impression—Severity of Illness scale rating ≥4 and Hamilton Depression Scale ≥18 at screening and baseline

Main Exclusion Criteria

- Significant risk of suicide
- Significant physical or other psychiatric illness that would interfere with study assessments
- Resistant depression
- Use of antidepressants or other psychotropic substances in past week
- Current formal psychotherapy or alternative treatments in past week or during study
- Electroconvulsive therapy during current episode

Treatment

- Patients were randomized in a 1:1 ratio to receive treatment with CIT 40 mg QD plus PP 5 mg BID (combination termed PP/CIT) or CIT 40 mg QD and placebo BID.

Assessments

- The Montgomery–Aberg Depression Rating Scale (MADRS) was administered at baseline and weeks 1, 2, 4, 6, and 8.
- Clinical Global Impression—Improvement scale (CGI-I) was assessed at weeks 1, 2, 4, 6, and 8.
- Safety assessments included reporting of adverse events (AEs), clinical laboratory evaluation, vital signs, electrocardiogram, and physical examination.

Statistical Analysis

- Analyses were performed using the intention-to-treat (ITT) population, comprising all randomized patients.
- Missing data points imputed using last observation carried forward (LOCF); in addition, a mixed effects model analysis of variance (MMRM) was used to measure missing data and mitigate LOCF bias.¹⁰
- Change in MADRS scores and prolactin levels from baseline were compared between groups using 2-sample t-test.
- Treatment effect differences for MADRS and CGI-I scores at weeks 1, 2, 4, 6, and 8 were estimated with MMRM.
- Global treatment effect differences over 4 and 8 weeks were estimated using MMRM.
- MADRS sustained full response (≥50% improvement from baseline of weeks 2 and 4) was compared using logistic regression.
- Discontinuation rates and AEs were compared using the Fisher exact test.

Results

Patient Characteristics and Discontinuations

- There were 165 patients in the ITT population.
 - 81% of patients were women; mean age was 40 years.
 - Mean duration of the current MDD episode was 9.72 days; mean (SD) total MADRS score was 32.6 (5.5).
 - There were no clinically important group differences in demographic and clinical characteristics (Table 1).

Table 1. Patient Demographic and Clinical Characteristics


	CIT (n=82)	PP/CIT (n=83)
Mean (SD) age, Y	39.7 (11.8)	40.1 (11.4)
Sex, n (%)		
Women	65 (77)	70 (84)
Men	17 (21)	13 (16)
Race, n (%)		
White	82 (100)	82 (99)
Black	0	1 (1)
Mean (SD) weight, kg	79.8 (23.7)	80.0 (22.2)
Mean (SD) duration current MDD episode, d	99.6 (43.1)	94.8 (37.7)
n (%) with duration >12 wk	46 (56)	43 (52)
Mean (SD) MADRS total score	32.6 (5.9)	32.7 (5.1)
n (%) with MADRS total score >30 (severe depression)	56 (71)	57 (69)
Mean (SD) score MADRS item P: pessimistic thoughts	3.1 (1.0)	2.9 (1.1)
Mean (SD) score MADRS item T: suicidal thoughts	1.7 (0.9)	1.6 (0.9)
Other psychiatric history not ongoing, n (%)	53 (65)	65 (78)

CIT=clomipramine, 40 mg once daily; MADRS=Montgomery–Aberg Depression Rating Scale; MDD=major depressive disorder; PP=CIT plus pimeloperazine 5 mg twice daily + clomipramine 40 mg once daily.

- Of the 165 randomized patients, 26% (21/82) of the CIT group and 17% (14/83) of the PP/CIT group discontinued treatment (Figure 1).
- More CIT (18% [15/82]) than PP/CIT (4% [3/83]) patients discontinued during the first 4 weeks ($P=0.002$; Fisher exact test).
- This higher frequency of discontinuation was less to followup (CIT, n=8; PP/CIT, n=6) and unwillingness to continue (CIT, n=5; PP/CIT, n=2).
- More patients in the CIT group (5% [4/82]) discontinued because of an AE (n=2 [2/83] with PP/CIT).
- 1 patient in each group discontinued because of lack of efficacy.

- Post hoc analysis determined that the mean (SD) change in MADRS score from baseline to week 8 was significantly smaller for patients dropping out between weeks 1 and 2 (−0.2 [2.2]; n=5, off-CIT group) compared with patients continuing past week 2 (−3.6 [5.8]; n=152; $P=0.01$; Wilcoxon test).

Figure 1. Cumulative Number of Discontinuations by Week of Clinic Visit (ITT)



Concomitant Medication and Treatment Compliance

- Concomitant medications taken by >10% of patients were analgesics (55%), sex hormones and modulators of the genital system (22%), drugs for acid-related disorders (22%), systemic antibiotic agents (19%), antiinflammatory drugs (18%), and drugs for asthma or other obstructive airway disease (17%).
- In both treatment groups, treatment compliance was >95%.

Accelerates the Antidepressant Effects of Citalopram

Ronald M. Crawford, MD,¹ Alex McConnachie, PhD,² Ian Ford, PhD,³ Ludo Haazen, MD,⁴ Erik Buntinx, MD,⁵


Atlanta, GA, USA; ²Stanford School of Medicine, Department of Psychiatry & Behavioral Sciences, Stanford, CA, USA;

³Germany; ⁴Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK; ⁵PharmaNeuroBoost N.V., Alken, Belgium

MADRS Scores

- There was significantly greater improvement in mean (SD) MADRS total score from baseline with PIPCT vs CII at week 1 [-0.7 (6.0) vs -0.0 (5.2), respectively; $P=0.007$) and week 4 [-15.1 (8.5) vs -12.1 (8.3); $P=0.03$, $t=1.71$, $P=0.08$ (Figure 2) but no difference between groups at week 8 [-17.3 (10.0) vs -16.2 (10.4); $P=0.40$, $t=0.1$, $P=0.92$].

Figure 2. Change from Baseline in MADRS Total Scores Over Time (ITT; LOCF)



CII=citalopram 40 mg once daily; ITT=Intent to treat; LOCF=Last observation carried forward; MADRS=Montgomery-Asberg Depression Rating Scale; PIPCT=piplazepam 5 mg twice daily + citalopram 40 mg once daily.

($P=0.007$).

- Mean (SD) MADRS scores were significantly lower with PIPCT vs CII at week 1 [26.3 (7.3) vs 28.4 (7.0), respectively; $P=0.05$, $t=1.70$, $P=0.03$] and week 4 [17.6 (8.8) vs 20.3 (9.6), $P=0.02$, $t=1.71$, $P=0.08$].

- In the ITT/LOCF population, PIPCT produced a superior global treatment effect for the MADRS total score in the first 4 weeks compared with CII, but not in the last 4 weeks (Table 2). *Note:* *Global treatment effect* refers to the mean difference in MADRS total score between the two groups over the first 4 weeks.

- There was a nonsignificant difference in global treatment effect over 8 weeks favoring PIPCT (Table 2).

Table 2. Global Treatment Effect Difference Between PIPCT and CII for MADRS Total and 8-wk Scores (ITT; LOCF)

	Global Treatment Effect Difference (95% CI) PIPCT - CII			
	4 wk	P Value	8 wk	P Value
MADRS total score	-2.6 [-4.4 to -0.9]	0.004	-1.9 [-3.8 to 0.1]	0.06
MADRS items				
Reduced sleep	-0.7 [-1.0 to -0.3]	<0.001	-0.6 [-0.9 to -0.2]	0.001
Reduced appetite	-0.4 [-0.7 to -0.1]	0.02	-0.3 [-0.6 to 0]	0.05
Reduced social difficulties	-0.2 [-0.5 to 0]	0.03	-0.1 [-0.3 to 0]	0.03
Pessimistic thoughts	-0.2 [-0.5 to 0]	0.02	-0.3 [-0.5 to 0]	0.02

CII=citalopram 40 mg once daily; ITT=Intent to treat; LOCF=Last observation carried forward; MADRS=Montgomery-Asberg Depression Rating Scale; PIPCT=piplazepam 5 mg twice daily + citalopram 40 mg once daily.

- In the MMRM analysis of the ITT population, PIPCT produced a superior global treatment effect for the MADRS items "reduced sleep" [4 wk and 8 wk] and "reduced appetite" [4 wk].

- There was a significantly better early full response with PIPCT (21% [17/80] vs CII (9% [6/67]; $P=0.05$, IT).

Table 3. Global Treatment Effect Difference Between PIPCT and CII for MADRS Total and 8-wk Scores (ITT; MMRM)

	Global Treatment Effect Difference (95% CI) PIPCT - CII			
	4 wk	P Value	8 wk	P Value
MADRS total score	-1.8 [-3.3 to 0.1]	0.07	-0.5 [-2.3 to 1.3]	0.57
MADRS items				
Reduced sleep	-0.6 [-0.9 to -0.2]	0.002	-0.4 [-0.8 to -0.1]	0.02
Reduced appetite	-0.3 [-0.7 to 0.0]	0.04	-0.2 [-0.5 to 0.1]	0.17

CII=citalopram 40 mg once daily; ITT=Intent to treat; MADRS=Montgomery-Asberg Depression Rating Scale; MMRM=mixed effect model for repeated measures; PIPCT=piplazepam 5 mg twice daily + citalopram 40 mg once daily.

CGI-I Scores

- At week 1, mean (SD) CGI-I scores were significantly lower with PIPCT [3.1 (0.9)] vs CII [3.5 (0.7); $P=0.01$, IT ; $t=1.71$, $P=0.08$].

Safety

- AEs were reported by 84% [67/80] of the CII group and 93% [77/83] of the PIPCT group.
- Number of discontinuations was generally similar between groups (Table 4); the most frequently reported AEs were gastrointestinal disorders and nervous system disorders.
- Mean (SD) serum prolactin elevation from baseline to week 8 was significantly greater with PIPCT (8.3 ng/mL [5.3]) compared with CII (0.7 ng/mL [6.0]; $P=0.003$, $t=3.61$), but there were no cases of hyperprolactinemia with week 8.
- There were no clinically relevant group differences in other laboratory results, vital signs, or vital signs.
- Body weight was greater in the PIPCT vs CII group from week 2-8 (global treatment effect difference over 8 wk, 0.9; 95% CI, 0.4-1.4; $P=0.001$, $t=3.17$); this was mostly driven by a greater weight reduction in the CII group.

○ There were no clinically relevant group differences in other laboratory results, vital signs, or vital signs.

○ Body weight was greater in the PIPCT vs CII group from week 2-8 (global treatment effect difference over 8 wk, 0.9; 95% CI, 0.4-1.4; $P=0.001$, $t=3.17$); this was mostly driven by a greater weight reduction in the CII group.

Table 4. Discontinuation Rate and Number of Patients in the Safety Population		
Adverse Event, n (%)	CII (n=80)	PIPCT (n=83)
Nausea	26 (33)	19 (23)
Headache	19 (24)	21 (25)
Diarrhea	13 (16)	10 (12)
Dry mouth	6 (8)	12 (15)
Fatigue	8 (10)	9 (11)
Hypertension	9 (11)	7 (8)
Upper respiratory tract infection	6 (8)	8 (10)
Dizziness	7 (9)	5 (6)
Nasopharyngitis	4 (5)	6 (7)
Tantrum	4 (5)	5 (6)
Vomiting	2 (3)	7 (8)
Night sweats	3 (4)	5 (6)
Cough	3 (4)	4 (5)
Lower respiratory tract infection	2 (3)	4 (5)
Influenza	2 (3)	4 (5)
Somnolence	1 (1)	6 (7)
Tiredness	4 (5)	2 (2)
Rash	4 (5)	2 (2)

CII=citalopram 40 mg once daily; PIPCT=piplazepam 5 mg twice daily + citalopram 40 mg once daily.

Conclusions

- In this randomized controlled trial in patients with MDD, addition of low-dose PIPCT to CII accelerated the clinical response compared with CII monotherapy.
- At 1 week of treatment, PIPCT produced a significantly greater improvement in MADRS symptoms from baseline compared with CII monotherapy.
- PIPCT also produced a superior global treatment effect on the MADRS during the first 4 weeks of the trial and significantly lower CGI-I scores at week 1 of treatment; PIPCT was numerically superior on MADRS change over 8 weeks but just failed to reach statistical significance.
- The addition of PIPCT to CII did not result in a different tolerability/safety profile.
- The observed lower discontinuation rate with PIPCT vs CII in the first weeks may be associated with a more rapid resolution of depressive symptoms in patients with MDD.

References

- Cooper BN, et al. *J Clin Intern Med*. 2008;25(3):551-560.
- Jekel JH, et al. *JAMA*. 2004;292(2):338-343.
- Keller MB, et al. *Am J Clin Psychopharmacol*. 2002;17(6):255-271.
- Simeon H, et al. *Am J Psychiatry*. 1997;154:163-165.
- Shulman K, et al. *Psychopharmacology: Neuroscientific Basis and Practical Application*. Cambridge, UK: Cambridge University Press; 2000.
- Janiszewski M and Tseitlin E. *Psychopharmacol Bull*. 2006;37(1):47-166.
- Burke E, et al. *Int J Psychopharmacol*. 2008;11(1):19-20.
- Perez-Moreno K, et al. *Med Sci Monit*. 2008;25(2):729-739.
- Mulderink CJ, et al. *Psychopharmacol Bull*. 2007;42(2):101-114.

Disclosures: Dr. Vinken and Dr. Crawford are employees of CTS Research, who conducted the research on behalf of PharmaNeuroBoost N.V. Dr. Haazen and Dr. Buntinx are employees of Alken-Möller N.V., a shareholder of PharmaNeuroBoost N.V. Dr. Housay, a representative of Alken-Möller N.V. and a shareholder of PharmaNeuroBoost N.V., is Chief Executive Officer, Chief Scientific Officer, and Managing Director of PharmaNeuroBoost N.V.